Portage, Michigan, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, at the Encore Boston Harbor.
Spencer Stiles, Group President, Orthopaedics and Spine, and Jason Beach, Vice President, Finance and Investor Relations will represent the Company in a session scheduled for 3:00 pm Eastern Time.
A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$364.60 |
| Daily Change: | -5.60 -1.51 |
| Daily Volume: | 1,218,290 |
| Market Cap: | US$139.390B |
September 09, 2025 July 31, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
